The primary objective of this study was to estimate the clinical and economic benefits derived from increasing the use of fixed-dose combinations of high-intensity statins and ezetimibe in the treatment of hypercholesterolemia in patients at high or very high risk of CV events, from the perspective of the Spanish National Health System (SNS).
